IOMAI

IOMAI is a biopharmaceutical company that specializes in the development and commercialization of vaccines and immune system stimulants, delivered via a transcutaneous immunization (TCI) patch. The company was founded in 1997 and is based in Gaithersburg, Maryland, USA.

History

IOMAI was founded in 1997 by Gregory Glenn, a former scientist at the Walter Reed Army Institute of Research. The company was initially focused on developing vaccines for influenza and traveler's diarrhea, but has since expanded its research and development efforts to include other infectious diseases.

Transcutaneous Immunization

Transcutaneous immunization (TCI) is a method of delivering vaccines and other immune system stimulants through the skin, rather than through traditional injection. IOMAI's TCI patch is a key component of its product development strategy. The patch is designed to deliver the active ingredient directly to the immune cells located in the skin, which can then respond to the antigen and produce a protective immune response.

Products

IOMAI's product pipeline includes vaccines for influenza, traveler's diarrhea, and anthrax, as well as a stimulant for the immune system. The company's influenza vaccine is currently in Phase II clinical trials, while its traveler's diarrhea and anthrax vaccines are in Phase I trials.

Acquisition by Intercell

In 2008, Intercell, an Austrian biopharmaceutical company, acquired IOMAI for approximately $189 million. The acquisition was intended to strengthen Intercell's vaccine development capabilities and expand its product portfolio.

See Also

• Biopharmaceutical
• Vaccine
• Transcutaneous immunization
• Intercell